Market Overview

Valeant Fails To Reach $100 On Intra-Day Basis For The First Time Since September 2013

Share:
Related VRX
Citron Compares Express Scripts To Philidor: 'Culprit Behind Pharmaceutical Price Gouging'
Bill Ackman's Pershing Square Q3 Shareholder Letter Weighs In On Valeant, Chipotle
Bill Ackman Comments on Valeant Pharmaceuticals International (GuruFocus)

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading lower by $4.23 at $93.63 in Wednesday's session.

Off the open, it failed to reach triple digits on an intra-day basis for the first time since September 13, 2013, when it peaked at $99.50. Since making the high, it has declined to $92.29 and has not been about to mount much of a rally.

There is one daily support level ahead of the low for the recent down move that stands at its October 30 low ($90.46).

Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.

Do you like this article? Do you have suggestions for improvement? Please email feedback@benzinga.com

Posted-In: Technicals Intraday Update Movers Trading Ideas

 

Related Articles (VRX)

View Comments and Join the Discussion!